VIZIR Randomized controlled trial in COVID-19
It is a shame that blue ribbon US academic medical centers failed to lead on randomized trials in the treatment of acute COVID-19
Even simple interventions were ignored by NIH and university medical centers, thus we waited for trials from elsewhere which have confirmed some of our early impressions of promising drugs in the McCullough, Zelenko, Raoult, and FLCCC Protocols for the early ambulatory treatment of COVID-19.
Ben Abdallah et al from Tunisia recently published the VIZIR trial (viral infection treatment with oral zinc: a randomized controlled trial in COVID-19) which randomized a spectrum of acute COVID-19 patients to zinc 25 mg po bid versus placebo.
Zinc has been known for decades to be an inhibitor of RNA-dependent polymerase. There was a 42 percent reduction in the primary composite of needing ICU admission or death.
It is noteworthy, that the two most common companion drugs for zinc, hydroxychloroquine and ivermectin were not mentioned anywhere in the paper.
Additionally, while the authors indicate they diligently recorded information about COVID-19 vaccination, none of the data are given in the paper.
We are left with justification for the continued use of zinc.
Patients were fortunate to have doctors and hospitals throughout the pandemic who followed multidrug protocols that included zinc among several other nutraceuticals.
I wonder how many hospitalized patients in the world never received a single tablet of zinc?
I am pleased that 50 mg elemental zinc (220 mg of zinc sulfate) has been in the McCullough Protocol since August 7, 2020.
See more here substack.com
Header image: Getty Images
Bold emphasis added
Please Donate Below To Support Our Ongoing Work To Expose The Lies About Covid 19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.